Proactiveinvestors USA & Canada Antibe Therapeutics Inc https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Antibe Therapeutics Inc RSS feed en Sun, 05 Jul 2020 01:53:54 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Antibe Therapeutics closes $28.75 million offering ahead of planned Phase 3 trial of ATB-346 https://www.proactiveinvestors.com/companies/news/923124/antibe-therapeutics-closes-2875-million-offering-ahead-of-planned-phase-3-trial-of-atb-346-923124.html Tue, 30 Jun 2020 14:52:00 -0400 https://www.proactiveinvestors.com/companies/news/923124/antibe-therapeutics-closes-2875-million-offering-ahead-of-planned-phase-3-trial-of-atb-346-923124.html Antibe Therapeutics unveils $25M bought deal offering to fund non-addictive analgesic drug pipeline https://www.proactiveinvestors.com/companies/news/921516/antibe-therapeutics-unveils-25m-bought-deal-offering-to-fund-non-addictive-analgesic-drug-pipeline-921516.html Tue, 09 Jun 2020 20:29:00 -0400 https://www.proactiveinvestors.com/companies/news/921516/antibe-therapeutics-unveils-25m-bought-deal-offering-to-fund-non-addictive-analgesic-drug-pipeline-921516.html Antibe Therapeutics unveils positive topline results from Phase 2B clinical trial of ATB-346 for osteoarthritis pain https://www.proactiveinvestors.com/companies/news/920832/antibe-therapeutics-unveils-positive-topline-results-from-phase-2b-clinical-trial-of-atb-346-for-osteoarthritis-pain-920832.html Mon, 01 Jun 2020 11:45:00 -0400 https://www.proactiveinvestors.com/companies/news/920832/antibe-therapeutics-unveils-positive-topline-results-from-phase-2b-clinical-trial-of-atb-346-for-osteoarthritis-pain-920832.html Antibe Therapeutics names former FDA official Dr Joseph Stauffer as chief medical officer https://www.proactiveinvestors.com/companies/news/918982/antibe-therapeutics-names-former-fda-official-dr-joseph-stauffer-as-chief-medical-officer-918982.html Wed, 06 May 2020 12:35:00 -0400 https://www.proactiveinvestors.com/companies/news/918982/antibe-therapeutics-names-former-fda-official-dr-joseph-stauffer-as-chief-medical-officer-918982.html Antibe Therapeutics expects results from Phase 2B study of pain drug ATB-346 within six weeks https://www.proactiveinvestors.com/companies/news/918749/antibe-therapeutics-expects-results-from-phase-2b-study-of-pain-drug-atb-346-within-six-weeks-918749.html Mon, 04 May 2020 12:55:00 -0400 https://www.proactiveinvestors.com/companies/news/918749/antibe-therapeutics-expects-results-from-phase-2b-study-of-pain-drug-atb-346-within-six-weeks-918749.html Antibe Therapeutics finishes Phase 2 trial for ATB-346; results expected in weeks https://www.proactiveinvestors.com/companies/news/916856/antibe-therapeutics-finishes-phase-2-trial-for-atb-346-results-expected-in-weeks-916856.html Tue, 07 Apr 2020 18:17:00 -0400 https://www.proactiveinvestors.com/companies/news/916856/antibe-therapeutics-finishes-phase-2-trial-for-atb-346-results-expected-in-weeks-916856.html Echelon rates Antibe Therapeutics as 'top pick' as investors eagerly await Phase II data from ATB-346 study https://www.proactiveinvestors.com/companies/news/916616/echelon-rates-antibe-therapeutics-as--top-pick--as-investors-eagerly-await-phase-ii-data-from-atb-346-study-916616.html Fri, 03 Apr 2020 16:52:00 -0400 https://www.proactiveinvestors.com/companies/news/916616/echelon-rates-antibe-therapeutics-as--top-pick--as-investors-eagerly-await-phase-ii-data-from-atb-346-study-916616.html American Council on Science and Health hails Antibe's ATB-346 as potential breakthrough in pain med https://www.proactiveinvestors.com/companies/news/914681/american-council-on-science-and-health-hails-antibe-s-atb-346-as-potential-breakthrough-in-pain-med-914681.html Tue, 10 Mar 2020 19:17:00 -0400 https://www.proactiveinvestors.com/companies/news/914681/american-council-on-science-and-health-hails-antibe-s-atb-346-as-potential-breakthrough-in-pain-med-914681.html NA Proactive news snapshot: Ozop Surgical, CytoDyn, Globex Mining, Heritage Cannabis UPDATE … https://www.proactiveinvestors.com/companies/news/913971/na-proactive-news-snapshot-ozop-surgical-cytodyn-globex-mining-heritage-cannabis-update--913971.html Fri, 28 Feb 2020 21:00:00 -0500 https://www.proactiveinvestors.com/companies/news/913971/na-proactive-news-snapshot-ozop-surgical-cytodyn-globex-mining-heritage-cannabis-update--913971.html Antibe Therapeutics enrolls last patient in Phase 2B dose-ranging study of lead drug ATB-346 https://www.proactiveinvestors.com/companies/news/913957/antibe-therapeutics-enrolls-last-patient-in-phase-2b-dose-ranging-study-of-lead-drug-atb-346-913957.html Fri, 28 Feb 2020 12:47:00 -0500 https://www.proactiveinvestors.com/companies/news/913957/antibe-therapeutics-enrolls-last-patient-in-phase-2b-dose-ranging-study-of-lead-drug-atb-346-913957.html Antibe Therapeutics reports positive progress in Phase 2B trials of ATB-346 https://www.proactiveinvestors.com/companies/news/913649/antibe-therapeutics-reports-positive-progress-in-phase-2b-trials-of-atb-346-913649.html Tue, 25 Feb 2020 15:05:00 -0500 https://www.proactiveinvestors.com/companies/news/913649/antibe-therapeutics-reports-positive-progress-in-phase-2b-trials-of-atb-346-913649.html Antibe Therapeutics sees article highlighting its anti-inflammatory drug published in medical journal https://www.proactiveinvestors.com/companies/news/913542/antibe-therapeutics-sees-article-highlighting-its-anti-inflammatory-drug-published-in-medical-journal-913542.html Mon, 24 Feb 2020 13:54:00 -0500 https://www.proactiveinvestors.com/companies/news/913542/antibe-therapeutics-sees-article-highlighting-its-anti-inflammatory-drug-published-in-medical-journal-913542.html Antibe Therapeutics bolsters executive team in preparation for ATB-346 commercialization https://www.proactiveinvestors.com/companies/news/910470/antibe-therapeutics-bolsters-executive-team-in-preparation-for-atb-346-commercialization-910470.html Mon, 13 Jan 2020 14:36:00 -0500 https://www.proactiveinvestors.com/companies/news/910470/antibe-therapeutics-bolsters-executive-team-in-preparation-for-atb-346-commercialization-910470.html NA Proactive news snapshot: Antibe Therapeutics, EuroLife Brands, Medgold Resources, NexTech AR Solutions UPDATE… https://www.proactiveinvestors.com/companies/news/908114/na-proactive-news-snapshot-antibe-therapeutics-eurolife-brands-medgold-resources-nextech-ar-solutions-update-908114.html Thu, 28 Nov 2019 21:30:00 -0500 https://www.proactiveinvestors.com/companies/news/908114/na-proactive-news-snapshot-antibe-therapeutics-eurolife-brands-medgold-resources-nextech-ar-solutions-update-908114.html Antibe Therapeutics running largest number of sites for any clinical trial in Canada in ATB-346 study https://www.proactiveinvestors.com/companies/news/908110/antibe-therapeutics-running-largest-number-of-sites-for-any-clinical-trial-in-canada-in-atb-346-study-908110.html Thu, 28 Nov 2019 13:41:00 -0500 https://www.proactiveinvestors.com/companies/news/908110/antibe-therapeutics-running-largest-number-of-sites-for-any-clinical-trial-in-canada-in-atb-346-study-908110.html Antibe Therapeutics is ready for a big push as it progresses pain management drug through clinical trials https://www.proactiveinvestors.com/companies/news/905097/antibe-therapeutics-is-ready-for-a-big-push-as-it-progresses-pain-management-drug-through-clinical-trials-905097.html Mon, 21 Oct 2019 13:00:00 -0400 https://www.proactiveinvestors.com/companies/news/905097/antibe-therapeutics-is-ready-for-a-big-push-as-it-progresses-pain-management-drug-through-clinical-trials-905097.html Antibe Therapeutics sees fiscal first quarter revenue rise thanks to higher sales in the United States https://www.proactiveinvestors.com/companies/news/901644/antibe-therapeutics-sees-fiscal-first-quarter-revenue-rise-thanks-to-higher-sales-in-the-united-states-901644.html Wed, 28 Aug 2019 13:35:00 -0400 https://www.proactiveinvestors.com/companies/news/901644/antibe-therapeutics-sees-fiscal-first-quarter-revenue-rise-thanks-to-higher-sales-in-the-united-states-901644.html Antibe Therapeutics: Phase 2B study of flagship drug ATB-346 to treat osteoarthritis pain ‘proceeding well’ https://www.proactiveinvestors.com/companies/news/901552/antibe-therapeutics-phase-2b-study-of-flagship-drug-atb-346-to-treat-osteoarthritis-pain-proceeding-well-901552.html Tue, 27 Aug 2019 12:35:00 -0400 https://www.proactiveinvestors.com/companies/news/901552/antibe-therapeutics-phase-2b-study-of-flagship-drug-atb-346-to-treat-osteoarthritis-pain-proceeding-well-901552.html Antibe Therapeutics to sell units to raise money to further develop lead osteoarthritis drug https://www.proactiveinvestors.com/companies/news/224378/antibe-therapeutics-to-sell-units-to-raise-money-to-further-develop-lead-osteoarthritis-drug-224378.html Tue, 23 Jul 2019 21:00:00 -0400 https://www.proactiveinvestors.com/companies/news/224378/antibe-therapeutics-to-sell-units-to-raise-money-to-further-develop-lead-osteoarthritis-drug-224378.html Antibe Therapeutics is looking to the future after successful past year https://www.proactiveinvestors.com/companies/news/313988/antibe-therapeutics-is-looking-to-the-future-after-successful-past-year-13988.html Thu, 04 Jul 2019 16:26:00 -0400 https://www.proactiveinvestors.com/companies/news/313988/antibe-therapeutics-is-looking-to-the-future-after-successful-past-year-13988.html Antibe Therapeutics hosts successful annual and special general meeting https://www.proactiveinvestors.com/companies/news/223238/antibe-therapeutics-hosts-successful-annual-and-special-general-meeting-223238.html Tue, 02 Jul 2019 23:56:00 -0400 https://www.proactiveinvestors.com/companies/news/223238/antibe-therapeutics-hosts-successful-annual-and-special-general-meeting-223238.html Antibe Therapeutics updates on Phase 2 progress of lead drug ATB-346 https://www.proactiveinvestors.com/companies/news/222800/antibe-therapeutics-updates-on-phase-2-progress-of-lead-drug-atb-346-222800.html Tue, 25 Jun 2019 17:30:00 -0400 https://www.proactiveinvestors.com/companies/news/222800/antibe-therapeutics-updates-on-phase-2-progress-of-lead-drug-atb-346-222800.html Antibe Therapeutics CEO Dan Legault on why the multibillion-dollar NSAID market needs disruption https://www.proactiveinvestors.com/companies/news/221077/antibe-therapeutics-ceo-dan-legault-on-why-the-multibillion-dollar-nsaid-market-needs-disruption-221077.html Fri, 07 Jun 2019 20:08:00 -0400 https://www.proactiveinvestors.com/companies/news/221077/antibe-therapeutics-ceo-dan-legault-on-why-the-multibillion-dollar-nsaid-market-needs-disruption-221077.html Antibe Therapeutics targets opioids with post-op pain drug https://www.proactiveinvestors.com/companies/news/313615/antibe-therapeutics-targets-opioids-with-post-op-pain-drug-13615.html Wed, 05 Jun 2019 15:49:00 -0400 https://www.proactiveinvestors.com/companies/news/313615/antibe-therapeutics-targets-opioids-with-post-op-pain-drug-13615.html Antibe Therapeutics targets US$9 billion market with second pipeline drug ATB-352 for severe pain https://www.proactiveinvestors.com/companies/news/221396/antibe-therapeutics-targets-us9-billion-market-with-second-pipeline-drug-atb-352-for-severe-pain-221396.html Mon, 03 Jun 2019 15:10:00 -0400 https://www.proactiveinvestors.com/companies/news/221396/antibe-therapeutics-targets-us9-billion-market-with-second-pipeline-drug-atb-352-for-severe-pain-221396.html Antibe Therapeutics is a potential game changer in pain management https://www.proactiveinvestors.com/companies/news/313052/antibe-therapeutics-is-a-potential-game-changer-in-pain-management-13052.html Wed, 17 Apr 2019 20:09:00 -0400 https://www.proactiveinvestors.com/companies/news/313052/antibe-therapeutics-is-a-potential-game-changer-in-pain-management-13052.html Antibe Therapeutic's Phase 2B trial safety results for pain drug ATB-346 published in British Journal of Pharmacology https://www.proactiveinvestors.com/companies/news/218693/antibe-therapeutic-s-phase-2b-trial-safety-results-for-pain-drug-atb-346-published-in-british-journal-of-pharmacology-218693.html Tue, 16 Apr 2019 12:23:00 -0400 https://www.proactiveinvestors.com/companies/news/218693/antibe-therapeutic-s-phase-2b-trial-safety-results-for-pain-drug-atb-346-published-in-british-journal-of-pharmacology-218693.html Antibe Therapeutics poised to disrupt the global pain management industry https://www.proactiveinvestors.com/companies/news/218520/antibe-therapeutics-poised-to-disrupt-the-global-pain-management-industry-218520.html Fri, 12 Apr 2019 20:00:00 -0400 https://www.proactiveinvestors.com/companies/news/218520/antibe-therapeutics-poised-to-disrupt-the-global-pain-management-industry-218520.html Antibe grants Kinght commercial rights for drug candidates https://www.proactiveinvestors.com/companies/news/119234/antibe-grants-kinght-commercial-rights-for-drug-candidates-119234.html Mon, 16 Nov 2015 14:32:00 -0500 https://www.proactiveinvestors.com/companies/news/119234/antibe-grants-kinght-commercial-rights-for-drug-candidates-119234.html Antibe Therapeutics plunges 80% on suspending lead drug’s phase I clinical trial https://www.proactiveinvestors.com/companies/news/105093/antibe-therapeutics-plunges-80-on-suspending-lead-drugs-phase-i-clinical-trial-59314.html Fri, 16 Jan 2015 14:22:00 -0500 https://www.proactiveinvestors.com/companies/news/105093/antibe-therapeutics-plunges-80-on-suspending-lead-drugs-phase-i-clinical-trial-59314.html Antibe Therapeutics seeks to fill market void with “ground-breaking” class of painkiller drugs https://www.proactiveinvestors.com/companies/news/97824/antibe-therapeutics-seeks-to-fill-market-void-with-ground-breaking-class-of-painkiller-drugs-48794.html Antibe Therapeutics is seeking to fill a vast market void with a “ground-breaking” class of painkiller drugs.  While the journey bringing the drug to market may be long and arduous, the end result appears to be well worth the toil, says president and CEO, Dan Legault. 

]]>
Wed, 09 Oct 2013 14:37:00 -0400 https://www.proactiveinvestors.com/companies/news/97824/antibe-therapeutics-seeks-to-fill-market-void-with-ground-breaking-class-of-painkiller-drugs-48794.html
Antibe Therapeutics completes second tranche of IPO https://www.proactiveinvestors.com/companies/news/96877/antibe-therapeutics-completes-second-tranche-of-ipo-47121.html Wed, 14 Aug 2013 19:08:00 -0400 https://www.proactiveinvestors.com/companies/news/96877/antibe-therapeutics-completes-second-tranche-of-ipo-47121.html